The investor presentation “MagSense® Technology: A New Diagnostic for Targeted Early Detection of Cancer” was presented at the 2017 Annual General Meeting. View the Investor Presentation.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance